We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Fluorescent Sensor Provides Low-Cost Diagnosis of Cystic Fibrosis

By LabMedica International staff writers
Posted on 17 Nov 2016
Print article
Image: Naturally fluorescing particles in body fluid samples were used to diagnose cystic fibrosis (Photo courtesy of Pennsylvania State University).
Image: Naturally fluorescing particles in body fluid samples were used to diagnose cystic fibrosis (Photo courtesy of Pennsylvania State University).
A new diagnostic test has been developed for cystic fibrosis and the new device provides a cheaper, easier way to detect levels of chloride in sweat, which are elevated in cystic fibrosis patients.

Chloride is an essential electrolyte that maintains homeostasis within the body, where abnormal chloride levels in biological fluids may indicate various diseases such as cystic fibrosis (CF). However, current analytical solutions for chloride detection fail to meet the clinical needs of both high performance and low material or labor costs, hindering translation into clinical settings.

Bioengineers at the Pennsylvania State University (University Park, PA, USA) first developed a citrate-based dye that emits fluorescent light. In the presence of chloride, however, the amount of light given off by the molecule diminishes: the more chloride, the less fluorescence. Sweat from eight healthy and five CF individuals were collected from each arm at a sweat clinic, where sweat from the right arm was analyzed by mercuric nitrate titration.

Absorbance spectra for the new test were recorded on an Infinite M200 Pro UV-vis spectroscopy, and fluorescence spectra were recorded on a FluoroMax-4 fluorospectroscopy at concentrations below 0.1 optical density (OD). After creating a detection system based on this principle, the team compared it to the chloride-detection method currently used in the clinic and found both tests gave similar results. The new test can detect chloride over a wider range of concentrations and, because it's automated, it avoids the problem of human error.

Seila Selimovic, PhD, program director of National Institute of Biomedical Imaging and Bioengineering (Bethesda, MD, USA), said, “This is an important step towards faster, more reliable diagnosis. The new sensing technology is cheap and easy to apply and, if used as part of a point-of-care device may allow more clinics to provide early cystic fibrosis tests. That is a great thing for the developed world, but is a game changer for the economically developing world, since early intervention can save lives in dealing with this devastating and all too common disease.” The study was first published online on August 30, 2016, in the journal Chemical Science.

Related Links:
Pennsylvania State University
National Institute of Biomedical Imaging and Bioengineering
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Molecular PCR-grade detection of Lyme bacteria right at the tick bite (Photo courtesy of En Carta Diagnostics)

Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes

Lyme disease, transmitted through tick bites, is a bacteria-caused illness that impacts 1.2 million individuals annually. The standard methods for diagnosing this disease include clinical examinations,... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more